In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Tzu-Jou ChenDepartment of Chemical Immunology and Proteomics, The Rockefeller University, New York, New York, 10065, USA.ORCID 0000-0002-5328-2000 Ya-Hui LinImmuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0001-9874-0012 Joshua D SchoenfeldImmuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0002-3970-9784 Lisa H F McGaryImmuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0001-6473-1177 Yan-Ting ChenImmuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0002-5156-3845 Korbinian N KroppImmuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0001-8104-7166 Beatrice ZhangMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0003-1636-600X Jahan RahmanDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0001-8755-5890 Tiffany L ZhangDepartment of Chemical Immunology and Proteomics, The Rockefeller University, New York, New York, 10065, USA.ORCID 0000-0003-4880-2195 Nathalie RopekDepartment of Chemical Immunology and Proteomics, The Rockefeller University, New York, New York, 10065, USA.ORCID 0000-0002-6326-8851 Cameron RobertsDepartment of Chemical Immunology and Proteomics, The Rockefeller University, New York, New York, 10065, USA.ORCID 0000-0002-0115-7013 Yuxi AiMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0001-6393-778X Kartikeya M MenonThe Evnin Family Laboratory of Computational Molecular Discovery, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-4589-4661 A Ari HakimiImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-0930-8824 Jiankun LyuThe Evnin Family Laboratory of Computational Molecular Discovery, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-0461-5454 Christopher A KlebanoffImmuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0001-9645-3896 Omar Abdel-WahabMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0002-3907-6171 Santosha A VardhanaImmuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.ORCID 0000-0002-3100-1298 Ekaterina V VinogradovaDepartment of Chemical Immunology and Proteomics, The Rockefeller University, New York, New York, 10065, USA.ORCID 0000-0003-3512-5375 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTargeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2018 to 2026
$21.5MThe Memorial Sloan Kettering Cancer Center SPORE in LeukemiaP50CA254838 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eytan Stein · 2021 to 2026
$16.8MGenetic and molecular basis for SRSF2 mutations in myelodysplasiaR01HL128239 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2015 to 2026
$8.0MWeill Cornell/Rockefeller/Sloan Kettering MST ProgramT32GM152349 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATHARINE C HSU · 2024 to 2026
$6.6MInterrogating the minor spliceosome to understand and treat leukemiaR01CA251138 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, BRADLEY, ROBERT K · 2020 to 2024
$3.3MMolecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.R37CA259177 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2021 to 2026
$3.1MSynthetic introns for selective targeting of RNA splicing factor-mutant leukemiaR01CA283364 · NCI · FRED HUTCHINSON CANCER CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2023 to 2026
$2.9MTargeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7MTri-Institutional PhD Program in Chemical BiologyT32GM136640 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI DEREK S TAN · 2020 to 2026
$2.4MNovel cell therapy approaches for molecularly defined subsets of therapy-resistant melanomaR01CA286507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2023 to 2026
$1.8MInvestigating altered T-cell metabolism during chronic antigen encounterK08CA237731 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VARDHANA, SANTOSHA · 2020 to 2024
$1.3MNCI NIH HHS F99 CA294267NCI NIH HHS K08 CA237731NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694NCI NIH HHS P50 CA254838NCI NIH HHS R01 CA242020NCI NIH HHS R01 CA251138NCI NIH HHS R01 CA283364NCI NIH HHS R01 CA286507NCI NIH HHS R37 CA259177NHLBI NIH HHS R01 HL128239NIGMS NIH HHS T32 GM136640NIGMS NIH HHS T32 GM152349
6 · The paper itselfAbstract
T cells exposed to persistent antigen in the context of chronic viral infections or cancer lose self-renewal and cytotoxic capacity. Several transcriptional, epigenetic, and metabolic drivers of this process have been identified. However, the post-transcriptional regulatory mechanisms influencing the proteome of dysfunctional T cells are not well understood. Here we present a time-resolved molecular landscape of human T cells during the development of chronic antigen-driven dysfunction. Persistent T cell receptor stimulation significantly remodeled the proteome, including changes in canonical T cell exhaustion-associated proteins and proteins related to mitochondrial function, redox homeostasis, nucleotide metabolism, and cell-cycle progression. Dysfunctional T cells displayed activation of stress response pathways that were recapitulated
Indexed as
chemical proteomicscysteine reactivitymetabolomicsmitochondriaredoxT cell exhaustion
Identifiers
PMID41846950
PMCPMC12991124
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390